Ildong’s exclusive distribution of LGLS’s Factive in Korea

Published: 2013-03-19 06:57:00

Updated: 2013-03-19 06:57:00

LG Life Sciences (LGLS) and Ildong Pharmaceutical announced Friday they have concluded an agreement that Ildong will exclusively distribute Factive (gemifloxacin), a synthetic broad-spectrum antibacterial agent for oral administration, in Korea over the next 10 years, while LGLS will focus on ove...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK